BeiGene
BGNE
#881
Rank
โ‚น1.860 T
Marketcap
โ‚น16,946
Share price
1.71%
Change (1 day)
5.70%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : โ‚น479.21 B

According to BeiGene 's latest financial reports the company's total assets are โ‚น479.21 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31โ‚น483.28 B-8.45%
2022-12-31โ‚น527.88 B-17.01%
2021-12-31โ‚น636.09 B55.55%
2020-12-31โ‚น408.92 B256.32%
2019-12-31โ‚น114.76 B-26.66%
2018-12-31โ‚น156.48 B134.2%
2017-12-31โ‚น66.81 B142.3%
2016-12-31โ‚น27.57 B255.44%
2015-12-31โ‚น7.75 B128.63%
2014-12-31โ‚น3.39 B365.41%
2013-12-31โ‚น0.72 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
โ‚น1.52 B-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น166.09 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA